Form 8-K - Current report:
SEC Accession No. 0001193125-23-238557
Filing Date
2023-09-20
Accepted
2023-09-20 16:05:35
Documents
12
Period of Report
2023-09-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d476127d8k.htm   iXBRL 8-K 26871
  Complete submission text file 0001193125-23-238557.txt   149073

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20230914.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20230914_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20230914_pre.xml EX-101.PRE 11268
6 EXTRACTED XBRL INSTANCE DOCUMENT d476127d8k_htm.xml XML 3343
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 231266558
SIC: 2834 Pharmaceutical Preparations